NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Ekso Bionics Holdings, Inc. (“Ekso Bionics” or the “Company”) (Nasdaq:EKSO) in the United States District Court for the Eastern District of New York on behalf of a class consisting of investors who purchased or otherwise acquired Ekso Bionics securities on the open market from March 15, 2017 through and including December 27, 2017 (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of the Securities Exchange Act of 1934.

On December 14, 2017, Ekso Bionics stated that “the Company’s internal control over financial reporting as of December 31, 2016 should no longer be relied upon and that a material weakness in the Company’s internal control over financial reporting existed as of such date.”  On this news, Ekso’s share price fell $0.15, or 6.17%, to close at $2.28 on December 15, 2017. Then, on December 27, 2017, during aftermarket hours, Ekso Bionics filed an amended annual report for 2016 and amended quarterly reports for the first three quarters of 2017.  On this news, shares of Ekso Bionics fell sharply during intraday trading on December 28, 2017.

Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm prior to the March 5, 2018 lead plaintiff motion deadline.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at or

Please visit our website at for more information about the firm.